PT Diagnos Laboratorium Utama

What PT Diagnos Laboratorium Utama does

PT Diagnos Laboratorium Utama is a publicly listed Indonesian laboratory chain headquartered in Jakarta, operating under ticker IDX:DGNS. Founded in 2009, the company provides a horizontal suite of clinical laboratory and medical support services, including blood tests, pharmaceutical warehousing, and blood and sperm bank operations, serving healthcare providers and patients across Indonesia. Its core business is a physical laboratory chain with standardized diagnostic testing infrastructure.

The company is pursuing a strategic vertical expansion into biotechnology through its announced acquisition of Singapore-incorporated biobank startup Asa Ren for US$24 million, representing a nearly 98% stake. Asa Ren specializes in curating diverse biological datasets intended to accelerate drug discovery and enable personalized medicine, giving Diagnos a foothold in higher-value biotech services that extend beyond routine diagnostics. This positions the combined entity as a laboratory services provider with an emerging biobank and translational research arm, targeting both traditional healthcare customers and biotechnology and pharmaceutical research clients. The business model relies on fee-for-service diagnostic testing in Indonesia, with no publicly disclosed pricing structure and no disclosed enterprise or B2B contract details.

Name

PT Diagnos Laboratorium Utama

Legal name

PT Diagnos Laboratorium Utama

Website

https://diagnos.co.id

Company type

Public

Founded year

2009

Operating status

Operating

Headcount range

101–250 employees

Short description

PT Diagnos Laboratorium Utama is a Jakarta-based, publicly listed Indonesian laboratory chain offering diagnostic testing, blood banking, and pharmaceutical warehousing services to healthcare providers and patients, with an expansion into biotech biobanking via its Asa Ren acquisition.

Ownership category

akta.pro rank

Product category

Clinical Laboratory Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071), Services-Health Services (8000)

akta.pro primary industry

Toxicology & Therapeutic Drug Monitoring Laboratories (HLAFAMAF)

akta.pro secondary industry

Women’s Health & Fertility Therapeutics (Digital) (HLACANAK)

Keywords

• Clinical laboratory services
• Diagnostic testing services
• Biobank services
• Medical support services
• Healthcare diagnostics

Headquarters

HQ city

Jakarta

HQ country

Indonesia

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain

Core offering

PT Diagnos Laboratorium Utama is a Jakarta-based listed laboratory chain that provides clinical diagnostic testing services, blood tests, pharmaceutical warehousing, blood and sperm bank operations, and other medical support services. The company is expanding into biotech and biobank services through its planned acquisition of Singapore-incorporated startup Asa Ren, targeting drug discovery and personalized medicine applications.

Product overview

PT Diagnos Laboratorium Utama is a Jakarta-based listed laboratory chain offering diagnostic laboratory services. The company operates as a single unified laboratory service offering. Through a planned acquisition of Singapore biobank startup Asa Ren for US$24 million, the company aims to expand into biotech capabilities, specifically leveraging Asa Ren's focus on diverse datasets to accelerate drug discovery and personalized medicine.

Differentiator

Problem solved

Functional benefit

Products and services

• Laboratory Diagnostic Services

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Asa RencoreStrategic or Co-development Partner · 18 April 2024PT Diagnos Laboratorium Utama announced plans to acquire Singapore-incorporated biobank startup Asa Ren for US$24 million, representing a nearly 98% stake. The acquisition aims to expand the company's biotech capabilities. Asa Ren focuses on diverse datasets to help accelerate drug discovery and personalized medicine, which complements the laboratory chain's existing services.

Scale indicators2 records

Direct peers

• Prodia Widyahusada: Indonesian publicly listed clinical laboratory chain offering diagnostic testing services to physicians, hospitals and patients nationwide. Direct competitor with overlapping test menu, customer base (Indonesian healthcare providers) and listed-equity funding model.
• PT Kimia Farma Diagnostika: Subsidiary of state-owned Kimia Farma operating clinical diagnostic laboratories across Indonesia. Direct competitor in Indonesian clinical lab services, with comparable product offering and similar customer segments.

Broad incumbents

• Bio Farma: Indonesian state-owned pharmaceutical and life sciences company with broader vaccine and biologics portfolio. Comparable through its life sciences and biological sample capabilities in Indonesia, overlapping with Diagnos's biobank/pharmaceutical warehousing business.
• Sonic Healthcare: Australian-headquartered global medical diagnostics company with extensive laboratory operations across Asia-Pacific. Comparable business model (clinical lab chain) and presence in the broader region, though much larger and more diversified than Diagnos.
• Quest Diagnostics: US-listed global clinical laboratory giant offering routine and specialized testing. Comparable business model (lab chain with diagnostic testing services) and reference lab capabilities, though vastly larger and operating in different geographies.
• Laboratory Corporation of America (Labcorp): US-listed global clinical laboratory company offering routine, esoteric and anatomic pathology testing plus bioanalytical/pharmaceutical development services. Comparable business model and now also expanding into biobank/biopharma services, mirroring Diagnos's strategic direction.

Regional players

• Raffles Medical Group: Singapore-listed integrated healthcare provider with laboratory and diagnostic services across Southeast Asia. Comparable as a regional healthcare/lab services operator with overlapping geographic reach and similar regulatory exposure.
• Bumrungrad Hospital: Thailand-listed flagship hospital group serving regional patients including Indonesians, with in-house diagnostic labs. Comparable as a Southeast Asian healthcare services provider with laboratory/diagnostic capabilities targeting the same patient pool.
• Singapore Medical Group: Singapore-listed specialist healthcare provider with diagnostics and laboratory-adjacent services. Comparable as a Southeast Asian listed healthcare services operator serving cross-border patients including Indonesians.

Others

• PT Siloam International Hospitals: Indonesia's largest private hospital chain, a major buyer and channel partner for clinical laboratory services. Comparable through its role as a customer/ecosystem participant that consumes lab testing services from operators like Diagnos.

Market position

Strengths5 records

Weaknesses5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/labdiagnos
• Facebookfacebook.com/LaboratoriumDiagnos

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PT Diagnos Laboratorium Utama